Article

Characterization of the prion protein binding properties of antisense oligonucleotides

2019-11-07

Abstract excerpt

Antisense oligonucleotides (ASOs) designed to lower prion protein (PrP) expression in the brain through RNAse H1-mediated degradation of PrP RNA are in development as prion disease therapeutics. ASOs were previously reported to sequence-independently interact with PrP and inhibit prion accumulation in cell culture, yet in vivo studies using a new generation of ASOs found that only PrP-lowering sequences were effe...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3e39fc0d-ec5d-53e2-8149-e006ca8295b7
DOI: 10.1101/816868

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Characterization of the prion protein binding properties of antisense oligonucleotidesDOI 10.1101/816868Read

Prion protein lowering is a disease-modifying therapy across prion disease stages, strains, and endpointsSemantic proximity Read

Divalent siRNA for prion diseaseSemantic proximity Read

Zinc Finger Repressors mediate widespread <i>PRNP</i> lowering in the nonhuman primate brain and profoundly extend survival in prion disease miceSemantic proximity Read

A single-cell map of antisense oligonucleotide activity in the brainSemantic proximity Read

Translating Antisense Technology into a Treatment for Huntington's Disease.Semantic proximity Read

Modulation of prion protein expression through cryptic splice site manipulationSemantic proximity Read

Depleting prion protein using splice-switching small moleculesSemantic proximity Read

Quantifying and Mitigating Motor Phenotypes Induced by Antisense Oligonucleotides in the Central Nervous SystemSemantic proximity Read

Short RNA chaperones promote aggregation-resistant TDP-43 conformers to mitigate neurodegenerationSemantic proximity Read

Treatment with a non-toxic, self-replicating anti-prion delays or prevents prion disease in vivoSemantic proximity Read

Therapeutic strategies for identifying small molecules against prion diseasesSemantic proximity Read

Dose-Dependent Lowering of Mutant Huntingtin Using Antisense Oligonucleotides in Huntington Disease PatientsSemantic proximity Read